Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/40382
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPugliatti, M-
dc.contributor.authorHartung, HP-
dc.contributor.authorOreja-Guevara, C-
dc.contributor.authorPozzilli, C-
dc.contributor.authorAiras, L-
dc.contributor.authorAlkhawajah, M-
dc.contributor.authorGrigoriadis, N-
dc.contributor.authorMagyari, M-
dc.contributor.authorVAN WIJMEERSCH, Bart-
dc.contributor.authorZakaria, M-
dc.contributor.authorLinker, R-
dc.contributor.authorChan, A-
dc.contributor.authorVermersch, P-
dc.contributor.authorBerger, T-
dc.date.accessioned2023-06-13T15:31:05Z-
dc.date.available2023-06-13T15:31:05Z-
dc.date.issued2022-
dc.date.submitted2023-06-06T09:06:37Z-
dc.identifier.citationFrontiers in Immunology, 13 (Art N° 1045101)-
dc.identifier.urihttp://hdl.handle.net/1942/40382-
dc.description.abstractIt has been over a year since people with multiple sclerosis (pwMS) have been receiving vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). With a negligible number of cases in which vaccination led to a relapse or new onset MS, experts around the world agree that the potential consequences of COVID-19 in pwMS by far outweigh the risks of vaccination. This article reviews the currently available types of anti-SARS-CoV-2 vaccines and the immune responses they elicit in pwMS treated with different DMTs. Findings to date highlight the importance of vaccine timing in relation to DMT dosing to maximize protection, and of encouraging pwMS to get booster doses when offered.-
dc.language.isoen-
dc.publisherFRONTIERS MEDIA SA-
dc.subject.otherCOVID-19-
dc.subject.othervaccines-
dc.subject.otherSARS-CoV-2-
dc.subject.othermultiple sclerosis-
dc.subject.otherdisease modifying therapies-
dc.subject.otherimmune response-
dc.subject.otheradverse events-
dc.titleAnti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in-
dc.typeJournal Contribution-
dc.identifier.volume13-
local.bibliographicCitation.jcatA1-
local.publisher.placeAVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND-
local.type.refereedRefereed-
local.type.specifiedReview-
local.bibliographicCitation.artnr1045101-
dc.identifier.doi10.3389/fimmu.2022.1045101-
dc.identifier.isi000891688600001-
local.provider.typeWeb of Science-
local.uhasselt.internationalyes-
item.validationecoom 2023-
item.fullcitationPugliatti, M; Hartung, HP; Oreja-Guevara, C; Pozzilli, C; Airas, L; Alkhawajah, M; Grigoriadis, N; Magyari, M; VAN WIJMEERSCH, Bart; Zakaria, M; Linker, R; Chan, A; Vermersch, P & Berger, T (2022) Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in. In: Frontiers in Immunology, 13 (Art N° 1045101).-
item.contributorPugliatti, M-
item.contributorHartung, HP-
item.contributorOreja-Guevara, C-
item.contributorPozzilli, C-
item.contributorAiras, L-
item.contributorAlkhawajah, M-
item.contributorGrigoriadis, N-
item.contributorMagyari, M-
item.contributorVAN WIJMEERSCH, Bart-
item.contributorZakaria, M-
item.contributorLinker, R-
item.contributorChan, A-
item.contributorVermersch, P-
item.contributorBerger, T-
item.accessRightsOpen Access-
item.fulltextWith Fulltext-
crisitem.journal.issn1664-3224-
crisitem.journal.eissn1664-3224-
Appears in Collections:Research publications
Files in This Item:
File Description SizeFormat 
fimmu-13-1045101.pdfPublished version635.75 kBAdobe PDFView/Open
Show simple item record

WEB OF SCIENCETM
Citations

4
checked on May 4, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.